Search for Biomarkers Crucial to Neurodegenerative Disease Therapeutics and Diagnostics

The debilitating neurodegenerative diseases Alzheimer’s and Parkinson’s have vexed healthcare in terms of both therapy and definitive antemortem diagnosis. The localized nature of the diseases in the central nervous system (CNS) makes the development of in vitro diagnostic (IVD) tests difficult. An incomplete understanding of the causes behind the diseases from a systems biology standpoint has also stalled clinical diagnostics development, even when CNS samples such as cerebrospinal fluid (CSF) are available. The incentive to develop marketable clinical assays has also been diminished to an extent by a lack of curative therapies for neurodegenerative diseases; clinicians are less apt to request or use a lab test to direct decision making for a disease without curative therapies. Still, clinical value exists for diagnostics able to detect pre-symptomatic onset of Alzheimer’s and Parkinson’s and inform earlier implementation of palliative care and neuroprotective therapy. Outside of clinical applications, lab diagnostics for the neurological diseases are in demand for life sciences research and clinical trials. Research use assays can assist in the characterization of neurodegeneration-associated biomarkers to improve understanding of cellular disease pathways and explore potential drug targets.

Critical Insights into IVD Market-Driving Segments – Kalorama’s Latest Reports in Cancer, Molecular and Infectious Disease Diagnostics

Kalorama Information’s latest in vitro diagnostics (IVD) titles delve into some of the fastest-growing and most critical areas of clinical diagnostics: cancer diagnostics, molecular assays and systems, and infectious disease tests. Together, these three IVD areas represent approximately 40% of the overall IVD market . The rate of growth for the combined segments is outpacing the growth of the overall IVD market by roughly two extra percentage points each year (+2% CAGR). Several subsegments of the cancer and molecular diagnostics markets are also growing at rates of over 8% each year. Kalorama Information has highlighted the superior market prospects of these IVD segments with three reports published in the past few months: The World Market for Molecular Diagnostics, 6th Edition, The World Market for Cancer Diagnostics, 6th Edition, and The World Market for Infectious Disease Diagnostic Tests.

Top Infectious Diseases in the IVD Market – Hepatitis

The following analysis is derived from Kalorama Information’s recently released global market research report: The Worldwide Market for Infectious Disease Diagnostic Tests.

This is the third in a series of five posts outlining the leading infectious diseases or infectious disease groups in terms of IVD market sales. Previous posts were for HIV/AIDS and respiratory tract infection tests.

Tests for viral hepatitis infections, primarily hepatitis C virus (HCV) and hepatitis B virus (HBV), are among the most common infectious disease tests run in clinical laboratories. Untreated, hepatitis infections can cause tremendous health problems after years or decades of latency. Similar to human immunodeficiency virus (HIV) infections, chronic hepatitis infections are treated with antiviral drugs. The efficacy of antiviral treatment is monitored using quantitative viral load assays. Additional applications for hepatitis diagnostics include the characterization and typing of hepatitis infections to optimize clinical treatment and the screening of donated blood for transfusion medicine. Hepatitis diagnostics represents a vast and diverse market; total IVD revenue is estimated well above $2 billion with demand across geographies and test settings from high-complexity clinical labs through points of care.

QIAGEN Bolsters Presence in Clinical NGS and Cancer Diagnostics Markets with GeneReader System Launch

Kalorama Information provides further analysis of QIAGEN and its competitors, including the companies’ cancer diagnostics and NGS product portfolios, in recent market research reports The World Market for Cancer Diagnostics, 6th Edition; Library Preparation and Target Enrichment for Next Generation Sequencing Product Markets; and Next Generation Sequencing Markets.

Several years of technology acquisition and internal development have culminated for QIAGEN with the launch of its comprehensive next-generation sequencing (NGS) workflow, the GeneReader system. The research and clinical NGS solution will expand QIAGEN’s market opportunity in NGS markets with product sales from sample preparation through automated interpretation of clinical sequencing results. Currently, Kalorama Information ranks QIAGEN behind Illumina, Agilent, Thermo Fisher and Fluidigm in market share for NGS library prep and target enrichment. Likewise, QIAGEN has held a relative secondary market share in the overall sequencing market. However, QIAGEN’s position in NGS markets is set to rise substantially, particularly as it more thoroughly addresses the market for sequencing assays in clinical oncology – a market space expected by Kalorama Information to grow at a substantially higher annual rate than the overall cancer diagnostics market through 2019.

Top Infectious Diseases in the IVD Market – HIV

The following analysis is derived from Kalorama Information’s recently released global market research report: The Worldwide Market for Infectious Disease Diagnostic Tests.

This is the second in a series of five posts outlining the leading infectious diseases or disease groups in terms of IVD market sales.

At over $2 billion in IVD market revenue, diagnostic tests for human immunodeficiency virus (HIV) infections are found across segments, including immunoassays, molecular assays, and blood screening assays. Treatment of chronic HIV infection using antiretroviral (ART) drugs has added significant value to the HIV test market and has driven demand for more sophisticated and higher value assays. The viral pathogen has influenced the reformulation of clinical and public health approaches to infectious diseases that treat them as chronic disease burdens rather than individual health episodes.


Subscribe to Kalorama Information Home RSS